KayoThera, Inc. is an early-stage therapeutics company focused on the development of a new class of cancer immunotherapeutics. KayoThera is developing therapies to treat late-stage and metastatic cancers including breast, lung, pancreatic, colorectal, brain, and kidney cancers.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/16/22 | $8,000,000 | Series A |
7G Bioventures Accelerator Life Science Partners  BioAdvance | undisclosed |
| 07/20/23 | $5,200,000 | Series A Extension |
Accelerator Life Science Partners BioAdvance Pier 70 Ventures WRF Capital | undisclosed |
